Cargando…

Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo

We observed a co-upregulation of the insulin-like growth factor receptor (IGF-1R)/AKT/mammalian target of rapamycin (mTOR) [InAT] axis and the mevalonate-isoprenoid biosynthesis (MIB) pathways in colorectal cancer stem cells (CSCs) in an unbiased approach. Hence, we hypothesized that the InAT axis m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharon, Chetna, Baranwal, Somesh, Patel, Nirmita J., Rodriguez-Agudo, Daniel, Pandak, William M., Majumdar, Adhip PN, Krystal, Geoffrey, Patel, Bhaumik B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558155/
https://www.ncbi.nlm.nih.gov/pubmed/25895029
_version_ 1782388588604817408
author Sharon, Chetna
Baranwal, Somesh
Patel, Nirmita J.
Rodriguez-Agudo, Daniel
Pandak, William M.
Majumdar, Adhip PN
Krystal, Geoffrey
Patel, Bhaumik B.
author_facet Sharon, Chetna
Baranwal, Somesh
Patel, Nirmita J.
Rodriguez-Agudo, Daniel
Pandak, William M.
Majumdar, Adhip PN
Krystal, Geoffrey
Patel, Bhaumik B.
author_sort Sharon, Chetna
collection PubMed
description We observed a co-upregulation of the insulin-like growth factor receptor (IGF-1R)/AKT/mammalian target of rapamycin (mTOR) [InAT] axis and the mevalonate-isoprenoid biosynthesis (MIB) pathways in colorectal cancer stem cells (CSCs) in an unbiased approach. Hence, we hypothesized that the InAT axis might regulate the MIB pathway to govern colorectal CSCs growth. Stimulation (IGF-1) or inhibition (IGF-1R depletion and pharmacological inhibition of IGF-1R/mTOR) of the InAT axis produced induction or attenuation of CSC growth as well as expression of CSC markers and self-renewal factors respectively. Intriguingly, activation of the InAT axis (IGF-1) caused significant upregulation of the MIB pathway genes (both mRNA and protein); while its inhibition produced the opposite effects in colonospheres. More importantly, supplementation with dimethylallyl- and farnesyl-PP, MIB metabolites downstream of isopentenyl-diphosphate delta isomerase (IDI), but not mevalonate and isopentenyl-pp that are upstream of IDI, resulted in a near-complete reversal of the suppressive effect of the InAT axis inhibitors on CSCs growth. The latter findings suggest a specific regulation of the MIB pathway by the InAT axis distal to the target of statins that inhibit 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR). Effects of IGF-1R inhibition on colonic CSCs proliferation and the MIB pathway were confirmed in an ‘in vivo’ HCT-116 xenograft model. These observations establish a novel mechanistic link between the InAT axis that is commonly deregulated in colorectal cancer and the MIB pathway in regulation of colonic CSCs growth. Hence, the InAT-MIB corridor is a novel target for developing paradigm shifting optimum anti-CSCs therapies for colorectal cancer.
format Online
Article
Text
id pubmed-4558155
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-45581552015-09-09 Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo Sharon, Chetna Baranwal, Somesh Patel, Nirmita J. Rodriguez-Agudo, Daniel Pandak, William M. Majumdar, Adhip PN Krystal, Geoffrey Patel, Bhaumik B. Oncotarget Research Paper We observed a co-upregulation of the insulin-like growth factor receptor (IGF-1R)/AKT/mammalian target of rapamycin (mTOR) [InAT] axis and the mevalonate-isoprenoid biosynthesis (MIB) pathways in colorectal cancer stem cells (CSCs) in an unbiased approach. Hence, we hypothesized that the InAT axis might regulate the MIB pathway to govern colorectal CSCs growth. Stimulation (IGF-1) or inhibition (IGF-1R depletion and pharmacological inhibition of IGF-1R/mTOR) of the InAT axis produced induction or attenuation of CSC growth as well as expression of CSC markers and self-renewal factors respectively. Intriguingly, activation of the InAT axis (IGF-1) caused significant upregulation of the MIB pathway genes (both mRNA and protein); while its inhibition produced the opposite effects in colonospheres. More importantly, supplementation with dimethylallyl- and farnesyl-PP, MIB metabolites downstream of isopentenyl-diphosphate delta isomerase (IDI), but not mevalonate and isopentenyl-pp that are upstream of IDI, resulted in a near-complete reversal of the suppressive effect of the InAT axis inhibitors on CSCs growth. The latter findings suggest a specific regulation of the MIB pathway by the InAT axis distal to the target of statins that inhibit 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR). Effects of IGF-1R inhibition on colonic CSCs proliferation and the MIB pathway were confirmed in an ‘in vivo’ HCT-116 xenograft model. These observations establish a novel mechanistic link between the InAT axis that is commonly deregulated in colorectal cancer and the MIB pathway in regulation of colonic CSCs growth. Hence, the InAT-MIB corridor is a novel target for developing paradigm shifting optimum anti-CSCs therapies for colorectal cancer. Impact Journals LLC 2015-03-29 /pmc/articles/PMC4558155/ /pubmed/25895029 Text en Copyright: © 2015 Sharon et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Sharon, Chetna
Baranwal, Somesh
Patel, Nirmita J.
Rodriguez-Agudo, Daniel
Pandak, William M.
Majumdar, Adhip PN
Krystal, Geoffrey
Patel, Bhaumik B.
Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
title Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
title_full Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
title_fullStr Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
title_full_unstemmed Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
title_short Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
title_sort inhibition of insulin-like growth factor receptor/akt/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558155/
https://www.ncbi.nlm.nih.gov/pubmed/25895029
work_keys_str_mv AT sharonchetna inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT baranwalsomesh inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT patelnirmitaj inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT rodriguezagudodaniel inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT pandakwilliamm inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT majumdaradhippn inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT krystalgeoffrey inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo
AT patelbhaumikb inhibitionofinsulinlikegrowthfactorreceptoraktmammaliantargetofrapamycinaxistargetscolorectalcancerstemcellsbyattenuatingmevalonateisoprenoidpathwayinvitroandinvivo